After a momentous 2024, Culver City-based ImmunityBio Inc., the immunotherapy company founded and majority-owned by ...
GlobalData on MSN6d
FDA authorises ImmunityBio’s BCG alternative to treat bladder cancerImmunityBio has gained US Food and Drug Administration (FDA) authorisation for an expanded access programme to supply an ...
FDA approves an expanded access program that would offer patients an alternative to Merck’s bladder cancer medication.
ImmunityBio (IBRX) is jumping 20% after the drug maker reported that the FDA had approved its use of an “alternative source ...
We recently published a list of 10 Stocks Stand Strong Amid Cautious Market Environment. In this article, we are going to ...
Hosted on MSN6d
ImmunityBio Surges On FDA Green Light For Expanded Bladder Cancer Vaccine Access — Retail Buzz IntensifiesShares of ImmunityBio Inc. surged 16.4% on Wednesday, marking their best session in over a month, and extended gains in after ...
The FDA has authorized an expanded access program that will allow for the use of a recombinant bacillus Calmette-Guerin product.
Drug company executives on Tuesday touted their industry’s work to keep and make Americans healthy during a Washington event.
PFS and OS benefits over chemotherapy were maintained for more than 2 years, and many patients had durable responses to ...
After rejecting ImmunityBio’s Anktiva last year, the FDA has cleared the drug as a treatment for bladder cancer, making it the company’s first commercial-stage product. Anktiva (nogapendekin ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback